Reflecting on this year's PHA conference in Dallas, columnist Mike Naple writes that connecting with community can be the ...

Most PAH patients who completed one year in a CS1 expanded access program had stable or improved clinical measures.

A study linked elevated blood levels of uric acid, a metabolic breakdown product often associated with gout, to a higher risk ...

At the Pulmonary Hypertension Association’s (PHA) biannual conference, it is easy to feel like you should be able to do more. There are sessions to attend, people to meet, dinners to join, and ...

Blocking a signaling pathway in certain white blood cells may prevent clots from obstructing blood flow and causing CTEPH, per a new study.

Nine members of the pulmonary hypertension (PH) community have received awards for their support of the Pulmonary ...

Oxiwear‘s wearable medical device, which continuously tracks oxygen levels in people with pulmonary hypertension (PH) and other heart or lung conditions, will now be covered by Medicare and certain ...

Subtle liver problems may contribute to the development of pulmonary arterial hypertension (PAH), suggesting complex communication between the lungs and liver along a so-called lung-liver axis, ...

Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly ...

Using artificial intelligence (AI) and analyzing genetic data focused on two primary biochemical processes, a team of scientists in China has identified two genes that appear to play key roles in ...